ACTRN12620001308987终止1 期
A Randomized, Observer-Blind, Placebo-Controlled, Phase I/II Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Receptor Binding Domain (RBD) SARS-CoV-2 HBsAg VLP (Adjuvanted with Aluminium (Alum) + CpG 1018/ Alum alone) COVID-19 Vaccine in Healthy Adults
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 79 Years（—）
- 性别
- All
入选标准
- •1. Male or Female aged 18 to 79 years (both inclusive)
- •a. Phase I: Subjects aged 18 to 45 years (both inclusive)
- •b. Phase II: Subjects aged 18 to 79 years (both inclusive)
- •2. Healthy participants as determined by medical history, physical examination, vital signs and clinical laboratory examination with no clinically significant deviations as judged by the Investigator at screening and randomization (Day 0)
- •3. Test negative for SARS-CoV-2 infection by RT-PCR test at screening
- •4. Test negative for SARS-CoV-2 IgG antibody presence at screening
- •5. Capable and willing to provide written informed consent prior to the performance of any study-specific procedures
排除标准
- •1. Receipt of medications or vaccines intended to prevent or treat COVID-19 infection in the past
- •2. Fever (non-axillary temperature > 37.5 ºC) or any other symptoms of infection that have not completely resolved including respiratory symptoms/illnesses within the past 3 days from randomization (Day 0)
- •3. Participants with a BMI > 35 kg/m2.
- •4. Presence of current active viral or bacterial infection, at screening and randomization (Day 0), which is determined by the Investigator to be of clinical significance
- •5. Individuals with history of any major pulmonary, cardiovascular, renal, neurological, metabolic, gastrointestinal, hepato-biliary, blood dyscrasia, uncontrolled hypertension and diabetes, clinically significant chronic pulmonary disease, asthma (with the exception of history of resolved childhood asthma), immunological and autoimmune diseases or any condition which in the opinion of the Investigator might interfere with the evaluation of the study objectives
- •6. Individuals currently working in occupations with high risk of exposure to SARS-CoV-2 (e.g. healthcare worker in direct care of COVID-19 patients, front line workers in COVID-19 hotspots/outbreak areas)
- •7. Pregnant or lactating women or willingness/intention to become pregnant during the study
- •8. Men and Women (of child-bearing potential) not agreeing to use adequate contraception during the study
- •9. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the Investigator, contraindicate intramuscular injection
- •10. Severely immunocompromised subjects. This exclusion category comprises a) subjects with solid organ transplantation; b) subjects with bone marrow transplantation; c) subjects under chemotherapy/radiotherapy; d) subjects with primary immunodeficiency; e) treatment with any anticytokine therapies. f) treatment with oral or intravenous steroids defined as daily doses of 10mg prednisolone or equivalent for longer than 3 months from the time of screening, or probable use of oral or intravenous steroids in the following four weeks
- •11. History of solid or non-solid malignancy or lymphoma (except basal cell carcinoma of the skin and cervical carcinoma in situ)
- •12. Known allergy to any component of the RBD SARS-CoV-2 HBsAg VLP Vaccine, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema.
- •13. A history of anaphylaxis to a vaccine, food, drug, toxin or other exposure.
- •14. Known hypersensitivity reactions to yeast.
- •15. Positive test result at screening for human immunodeficiency virus (Types 1 or 2) antibody, hepatitis B surface antigen, or hepatitis C virus antibody.
- •16. Clinical laboratory tests of blood and urine not within the normal range and show clinically relevant deviations as judged by the Investigator
- •17. History of demyelinating disease or Guillain Barre syndrome
- •18. Eczema or other significant skin lesion or infection at the site of vaccination
- •19. Planned or actual receipt of any vaccine other than the study intervention within 30 days before and after each study vaccination
- •20. Positive screen for drugs of abuse or alcohol (breath test) at screening and randomization (Day 0).
- •21. Participants who currently smoke 10 cigarettes or equivalent per day
- •22. Subjects not willing to/unable to comply with study procedures
- •23. Participating in any other study and have received any other investigational medication or device within 30 days prior to randomization or are taki
研究者
相似试验
进行中（未招募）
1 期
A Study to Assess Safety, Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy AdultsEbolaMedDRA version: 20.0 Level: PT Classification code 10014071 Term: Ebola disease System Organ Class: 10021881 - Infections and infestationsEUCTR2015-000596-27-GBJanssen Vaccines & Prevention BV421
进行中（未招募）
1 期
COVID-19 Vaccine in Adults 18 Years of Age or OlderCovid-19MedDRA version: 23.1Level: LLTClassification code 10084465Term: COVID-19 vaccinationSystem Organ Class: 100000004865EUCTR2020-005576-35-HUMedicago R&D Inc.30,000
已完成
2 期
Safety, Tolerability and Immunogenicity Study of 2-Dose Heterologous Regimens for Ebola vaccines Ad26.ZEBOV/MVA-BN-FiloEbolaEbola VaccinePACTR201608001734218Janssen Vaccines & Prevention B.V575
进行中（未招募）
1 期
A Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64 Years of AgeEUCTR2017-001239-38-DEMedicago R&D Inc.10,000
进行中（未招募）
1 期
A Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64 Years of AgeSeasonal influenzaMedDRA version: 20.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-001239-38-FIMedicago R&D Inc.10,000